Thomas Civik insider trades

Open-market stock purchases and sales by Thomas Civik, Interim CEO at Pyxis Oncology, Inc, from SEC Form 4 filings since Jan 1, 2018.

Track record: 0% of 1 scored buy are up 5% or more since purchase, averaging -87%.

Recent trades

DateStockTradeValue
Feb 3, 2026PYXS Pyxis Oncology, IncBought (not open market)—
Jan 28, 2026RPTX Repare Therapeutics IncSold (not open market)—

Companies traded

  • PYXS Pyxis Oncology, Inc: 1 buy, last Feb 3, 2026
  • RPTX Repare Therapeutics Inc: 1 buy, last Jan 28, 2026
  • FPRX Five Prime Therapeutics, Inc: other filings, last Apr 16, 2021
  • FMI Foundation Medicine, Inc: other filings, last Jul 31, 2018

Get free alerts when Thomas Civik files a new trade →